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Abstract
Background: A better understanding of the quality of cellular immune responses directed against molecularly
defined targets will guide the development of TB diagnostics and identification of molecularly defined, clinically
relevant M.tb vaccine candidates.
Methods: Recombinant proteins (n = 8) and peptide pools (n = 14) from M. tuberculosis (M.tb) targets were used to
compare cellular immune responses defined by IFN-γ and IL-17 production using a Whole Blood Assay (WBA) in a
cohort of 148 individuals, i.e. patients with TB + (n = 38), TB- individuals with other pulmonary diseases (n = 81) and
individuals exposed to TB without evidence of clinical TB (health care workers, n = 29).
Results: M.tb antigens Rv2958c (glycosyltransferase), Rv2962c (mycolyltransferase), Rv1886c (Ag85B), Rv3804c
(Ag85A), and the PPE family member Rv3347c were frequently recognized, defined by IFN-γ production, in blood
from healthy individuals exposed to M.tb (health care workers). A different recognition pattern was found for IL-17
production in blood from M.tb exposed individuals responding to TB10.4 (Rv0288), Ag85B (Rv1886c) and the PPE
family members Rv0978c and Rv1917c.
Conclusions: The pattern of immune target recognition is different in regard to IFN-γ and IL-17 production to
defined molecular M.tb targets in PBMCs from individuals frequently exposed to M.tb. The data represent the first
mapping of cellular immune responses against M.tb targets in TB patients from Honduras.
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Background
9.4 million individuals are newly diagnosed with TB
and two billion people are latently infected with M.tb
worldwide; twenty two ‘High Burden Countries’ (HBC)
account for 80% of TB cases. Brazil, the only HBC in
America, accounts for 35% of TB cases within the region
[1-3]. Honduras ranks number eight on the list of coun-
tries with a high TB burden in Latin America and second
in Central America [3,4]. 2901 TB cases were identified in
Honduras during 2010, with an estimated incidence rate
of 51/100,000 individuals [5]. The majority of patients with
TB reside in three regions, i.e. Region Metropolitana de
Cortes, the Region Departamental de San Pedro Sula and
the Region Metropolitana de Tegucigalpa. Several factors,
i.e. poor nutrition, HIV-M.tb co-infection, chronic (non-
infectious) diseases, overcrowding, drug and alcohol abuse,
affect the quality and magnitude of immune responses and
subsequently the clinical course of TB [6].
Bacteriological diagnosis for pulmonary (and extra-
pulmonary) TB in Honduras relies on smear microscopy-
acid fast staining (AF-S), sputum culture on Löwenstein
Jensen solid media and drug susceptibility testing
(DST). TB diagnosis is supported by clinical findings
(e.g. weight loss, coughing), individual patient history,
epidemiology and X-rays. The tuberculin skin test
(TST) is less frequently performed. The interferon
gamma release assay (IGRA) is used for case finding in
non-endemic countries as well as a corroborative test in
specific populations such as children, patients with
extra-pulmonary TB or immune-compromised individ-
uals [7-9], IGRAs are not used to differentiate between
active and latent TB. Therefore, there is still an unmet
need for novel diagnostic tests to reliably diagnose
extra-pulmonary TB, to differentiate between latent vs
active TB or to indicate ‘immune protection’ and effective
immune-surveillance in patients with latent TB. The
testing of IFN-γ as well as IL-17 in anti-M.tb immune
responses is biologically and clinically relevant. Both cyto-
kines are involved in the recruitment of neutrophils,
granuloma formation and in anti-M.tb directed immune
responses [10]; diminished Th1 and Th17 responses ap-
pear to be associated with higher rates of extrapulmonary
TB [11]; vice versa, expression of SOCS3 is associated with
increased IL-17 production along with T-cell exhaustion
(in peripheral blood cells from patients with TB [12].
Not only the nature of the immune responses, defined
by cytokine production, yet also the nature of the M.tb
encoded targets may determine the strength and magni-
tude of the anti-M.tb response. Cellular immune recogni-
tion of M.tb antigens, defined by cytokine production,
may reflect preferential expression of M.tb proteins during
the active and dormant phase of the infection [13-16].
The aim of this study was to compare M.tb specific cellu-
lar immune responses in blood from individuals with
active pulmonary (symptomatic) TB and individuals who
have been frequently exposed to M.tb in response to
antigens preferentially expressed by active and dormant
M.tb.
Methods
Study site and subjects
The Honduran population receives (after birth) BCG
vaccination since 1977. Different BCG vaccine strains
have been used, the current BCG is provided by the
Serum Institute, India, through WHO/UNICEF/GAVI.
Honduras has a considerable TB incidence and limited
resources in health care structures, including X-ray
facilities. The definition of a “clean” and well defined
(non-TB+) control group has therefore been challen-
ging. The TST was not implemented in this study, since
it is not routinely performed due to high variability in
cut off interpretations and subsequent variant clinical
decision making. 148 subjects were enrolled in the study
between August 2008 and May 2010 in Tegucigalpa,
Honduras at Instituto Nacional Cardiopulmonar (INCP)
and at the Health Center El Manchen. The median age
of the participants was 49 years, 62% of the study partici-
pants were female. Each subject was recruited after in-
formed consent; HIV-testing and counseling was offered
to each participant. A rapid HIV-1/HIV-2 antibody test
(Abbott Laboratories) was used to screen for HIV infec-
tion. Clinical data were collected from hospital records
and through structured interviews. Heparinized blood and
sputum samples were obtained from each donor after
written informed consent, morning (instant) sputum sam-
ples were collected after the interview and inclusion in the
study. For hospitalized patients, sampling was performed
in the morning as part of the diagnostic workup (3 days
morning samples). The population was divided into three
groups based on their clinical status and bacteriological
results: Group1: TB + (n = 38) (M.tb culture and AFS
positive, pulmonary TB) prior to initiation of DOTS;
Group 2: TB- (n = 81) respiratory symptomatic patients
(asthma, non-TB pneumonia, chronic-obstructive pul-
monary disease, lung cancer, pharyngitis). Both outpatients
and inpatients (in order to rule out TB, M.tb culture and
AFS negative) were included in the Group 2 patients.
Group 3: TB- (n = 29) health care workers from the TB
units, exposed to M.tb (M.tb culture and AFS negative, no
clinical signs of TB or any respiratory symptoms). LTBI
was not discriminated between groups 2 and 3; however,
the IGRA test was performed in both groups. All subjects
tested HIV-negative. The study protocol was approved by
the Institutional and National Ethical Committee, Instituto
Nacional Cardiopulmonar and Comite de Etica en
Investigación Biomédica (No. IRB 00003070).
Antigens used for T-cell stimulation assays are listed
in Table 1. Pools of 15-mer long peptides, overlapping
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by 7 amino acid residues (covering the entire protein),
were synthesized by JPT Peptide Technologies, Berlin,
Germany. Synthetic peptides and recombinant protein
(purity > 85%) were used at final concentration of 1 μg/ml
and 5 μg/ml respectively. The antigens Rv3804c, Rv1886c,
Rv0288 and Rv0959 were kindly provided by the AERAS
Global TB Foundation (AERAS, Rockville, USA). Recom-
binant proteins Rv3875 and Rv3874 were purchased from
Table 1 Summary of M.tb test targets
Peptides
Gene
locus
RefSeq M.tb Antigens aa Comment
Rv0447c NP854118
(Pool 1)
Probable cyclopropane fatty acyl
phospholipid synthase.
427 Methyl transferase activity. Cyclopropane fatty acyl phospholipid synthase
activity. Lipid biosynthetic process [17,18]
Rv2940c YP_976584
(Pool 2)
Mycocerosic acid synthase 2111 Lipid biosynthetic process. Oxido-reduction and transferase activity, Cofactor
binding. Location at the cell wall. [17,19-23]
Rv3347c YP_177963
(Pool 3)
PPE family protein 3157 Function unknown. Gly-Ala-Asn rich protein, interacts with the host system
by inhibition of antigen processing. [18,23-26]
Rv2453c CAA16030
(Pool 4)
Probable molybdopterin-guanine
dinucleotide biosynthesis Protein A
201 Molybdenum cofactor biosynthesis. Molecular function as GTP binding.
Located at the cytoplasm membrane. [18,23,24,27]
Rv1886c CAB10044
(Pool 5)
Antigen 85B 325 Fibronectin binding protein. Acyltransferase activity. Secreted protein, also
located at cell wall, plasma membrane. [18,28-31]
Rv1690 CAB10947
(Pool 6)
Probable lipoprotein 127 Putative uncharacterized protein. Protein binding, cellular component
plasma membrane.[18,24,32]
Rv3019c CAA16104
(Pool 7)
ESAT-6 like protein 96 Belongs to ESAT-6 (esx) family, Protein-protein interaction [18,24]
Rv2957 CAB05419
(Pool 8)
PGL/p-HBAD biosynthesis glycosyltrans-
ferase MT3031
256 Glycosyl transferase activity, transferring hexosyl groups. Glycolipid
biosynthetic function. Identified as a drug target. [18,24,30,33,34]
Rv1085c CAA17201
(Pool 9)
UPF0073 membrane protein 242 Belongs to the UPF0073 (HIy-III) family. Cytolysis. Sub cellular location in cell
membrane [18,24]
Rv0066c CAA16247
(Pool 10)
Isocitrate dehydrogenase, NADP-
dependent- icd2.
745 Oxidoreductase function. NAD or NADH binding. Isocitrate dehidrogenase
(NADP+) activity. Magnesium ion binding. Protein homodimerization.
[18,22-24,35,36]
Rv2958c CAB05418
(Pool 11)
PGL/p-HBAD biosynthesis glycosyltrans-
ferase
428 Glycolipid biosynthetic process, pathogenesis, Glycosyl transferase activity.
Immune evasion or - tolerance [18,22,24,33,37]
Rv2962c CAB05415
(Pool 12)
PGL/p-HBAD biosynthesis rhamnosyl-
transferase
449 Glycolipid biosynthetic process, pathogenesis. Glycosyl transferase activity.
Evasion or tolerance concerning to the host immune response.
[18,22,24,30,33,37]
Rv3804c/
1886
CAA17868/
CAB10044
Ag85A/Ag85B Fibronecting binding
protein peptide pool
338/
325
Belongs to the Ag85 family, contains Esterase D. Possesses mycolyl
transferase activity. [28,29,38-41]
Proteins
Rv3804c CAA17868 Ag85A. Secreted antigen 85A. Mycolyl
transferase 85A. fbpA. Ag85 complex
338 Responsible for high affinity of mycobacteria to fibronectin. Possesses
mycolyl transferase for biogenesis of trehalose dimycolate.
[22,23,29,30,38-40,42-44]
Rv1886c CAB10044 Ag85B. Secreted antigen 85B. Mycolyl
transferase 85B. fbpB. Ag85 complex
325 Fibronectin binding protein. Acyltransferase activity. Response to antibiotic.
Secreted protein also located at cell wall, extracellular region.
[28-30,36,38,40,41,45]
Rv3875 CAA56099 ESAT-6. 6 KDa early secretory antigenic
target. esxA
95 Function unknown. Elicit high level of IFNgamma during the first phase of
protective immune response. Secreted protein, cell wall and cytoplasm.
[46-54]
Rv3874 CAA17966 CFP-10. 10 KDa culture filtrate antigen 100 ESAT-6 like protein esxB. Forms a tight 1:1 complex with EsxA. Protein
binding. Host cell surface binding. Pathogenesis. Protein secretion.
[22,47-49,51,53,54]
Rv0754 CAE55319 PE_PGR11. PE-PGRS family protein 584 Member of M.tb PE family. PGRS subfamily gly-rich proteins. Unknown
function. Protein existence predicted. [18,21]
Rv0978c CAE55343 PE_PGR17. PE-PGRS family protein 331 Member of M.tb PE family. PGRS subfamily gly-rich proteins. Unknown
function. Protein existence predicted. [18,55,56]
Rv1917c CAE55440 PPE34. PPE family protein 1459 Member of M.tb PPE family. Glycin rich proteins. Unknown function. [18,57]
Rv0288 CAA17363 TB10.4. Low molecular weight protein.
(M.tb)
96 Belongs to theESAT-6 (esx) family. Molecular function protein binding.
Involved in virulence. Immunogenic. [18,24,58-61]
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Statens Serum Institute (SSI, Copenhagen, Denmark). The
recombinant PPE-proteins Rv0754, Rv0978c and Rv1917c
were produced by Professor K. N. Balaji, Bangalore, India
[55,62-64]. A mixture of Staphylococcal Enterotoxin A
and B, (SEA/SEB; 10 ng/mlSigma Aldrich, USA) was used
as the positive control for T-cell reactivity.
Whole blood assay
The whole blood assay (WBA) was used to determine
IFN-γ and IL-17 production in response to M.tb antigens.
Venous whole blood was obtained using heparinized blood
collection tubes and diluted 1:2.5 in RPMI 1640-medium
supplemented with 1% Hepes, 0.5% Penicillin/ (100 IU/ml)
and streptomycin (10 mg/ml), (Gibco Invitrogen). 100 μl of
diluted blood was added into 96-well round bottom plates
(Nunc, Roskilde, Denmark) in duplicate wells pre-coated
with the specific antigen diluted in 100 μl medium.
Cultures were incubated at 37°C, 5% CO2. After 7 days,
75 μl of cell culture supernatant was removed from
each duplicate well, pooled, and stored at −80°C until
IFN-γ and IL-17 were determined by ELISA.
IFN-γ and IL-17A determination
IFN-γ and IL-17A (IL-17) in cell culture supernatants
was measured by ELISA (Eli-pair DIACLONE, Biosite,
Stockholm, Sweden). The assays were performed according
to the manufacturer’s instruction. In brief, Nunc-Immuno™
Maxisorp 96-well plates (Nunc, GTF, Stockholm, Sweden)
were coated with the specific capture antibody over-
night at 4°C. The plates were then washed with PBS
containing 0.05% tween-20 and then blocked with PBS
containing 5% bovine serum albumin (BSA, Karolinska
Hospital, Stockholm, Sweden). Supernatants collected
from WBA (150 μl) were thawed and diluted (1:1.47 in
IFN-γ [75 μl] and 1:1.91 for IL-17 [55 μl] with PBS
containing 1% BSA. Values were multiplied by their corre-
sponding dilution factor, background from un-stimulated
medium control were subtracted from each antigen
response both for IFN-γ and IL-17; the cytokine concen-
tration was expressed in pg/ml. The detection range for
IFN-γ was 400–7 pg/ml and for IL-17 100–3.1 pg/ml. An
additional standard IFN-γ recombination protein (pur-
chased from R&D, Minneapolis, MN, USA) was used
as an internal control to gauge for differences between
ELISA assay performances.
Interferon gamma release assay (IGRA)
Quantiferon TB-Gold in tube (QFT-GIT) (Cellestis,
Copenhagen, Denmark) [65], was performed. Briefly,
1 ml of venous blood was collected directly into three
tubes containing TB-specific antigens, mitogen and nil
control. Tubes were incubated at 37°C, 5% CO2 for 16
to 24 hours before centrifugation at 3000 g for 15 min.
The plasma was collected and stored at +4°C until IFN-γ
detection within two weeks. ELISA was performed as
described by the manufacturer, in brief, 50 μl of conjugate
was added as well as 50 μl of test sample; diluted stan-
dards were added to designated wells followed by 2 hours
incubation. After washing, 100 μl of substrate solution
were added to wells and incubated for 30 minutes,
followed by 50 μl of enzyme stopping solution. OD values
were calculated using the Software A-QTF-2.5-02 2.5, a
free online source provided by Cellestis validating the
assay by internal quality controls and setting the cut off
for positive results at >0.35 International units (UI)/ml.
Sputum based acid-fast staining (AF-S) and Löwenstein
Jensen (LJ) culture
Acid fast staining (Ziehl-Neelsen technique) was performed
to visualize the acid-fast bacilli in sputum samples.
Samples were further cultured in duplicate at 37°C and
periodically revised up to 8 weeks (Löwenstein Jensen
selective media produced at the Research lab). In 14/
148 individuals, no cultures could be initiated due to
inadequate sputum procurement; the contamination
rate of cultures was 2/132. Positive cultures were confirmed
using standard biochemical tests, i.e. niacin, reduction
of nitrates and catalase activity [66]. Quality control of
Löwenstein-Jensen media was routinely performed
using M.tb control strains at the microbiology depart-
ment of the Hospital.
Statistical analysis
Data were explored using dotplot and barplot analysis. A
t-test was used to examine differences in IFN-γ and IL-17
production between groups. An adjustment for multipli-
city was applied on the resulting p-values from the tests,
only those antigens that showed significant difference at
5% level were discussed. We used the R software pairwise
t-test function to compare the treatment group means
with pooled Standard Deviation. The ANOVA test was
performed in order to confirm significant differences
between groups as well as a pairwise t-test and the Holm
adjustment method for multiple corrections.
Results
Increased IFN-γ production to M.tb antigens in blood
from health care workers exposed to M.tuberculosis as
compared to TB patients
IFN-γ production in response to M.tb target antigens
(overview see Table 1) was analyzed in blood from the
study participants (n = 148). We identified a significant
difference in IFN-γ production between the groups (see
Figure 1, Table 2 and Additional file 1: Table S1a-c) i.e. a
different magnitudes of IFN-γ production in response to
(peptide cocktails) Rv2958c, Rv2962c, Rv3347c, Rv3804c,
and Rv1886c (protein) between groups 1 (TB+) and 3
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(health care workers); the antigens Rv2958c and Rv2962c
were differentially recognized between group 2 (non-
TB pulmonary diseases) and 3 (health care workers).
Immune cells from individuals in group 2 (TB-,
other respiratory diseases) and group 3 (exposed to
TB, no clinical TB uninfected) produced significantly
higher levels of IFN-γ in response to stimulation with
Rv1886c (Ag85B) Rv2958c (glycosyl-transferase) and
Rv2962c (pHBAD biosynthesis rhamnosyltransferase).
The recombinant protein antigens Rv3804c (Ag85A)
and Rv3347c (PPE family member) induced the strongest
IFN-γ production in blood from group 3 (M.tb exposed
individuals) as compared to TB + individuals (group 1).
A head-to-head comparison between overlapping peptides
for Rv1886c (Ag85B) and the recombinant protein
(Table 2) yielded a similar trend (p = 0.015) for differences
between group 1 and 3 (using peptides as the assay target)
as well as for testing the recombinant protein (comparison
between groups 1 and 3, p = 0.002).
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Figure 1 IFN-γ boxplots of immune reactivity in blood stimulated with antigens/peptides that showed significant differences between
groups (group 1, TB + patients, group 2, TB- other pulmonary diseases, group 3, frequent M.tb exposure, yet clinically healthy).
Antigens were identified after testing a broad panel of M.tb antigens (see Table 1). Only statistically significant different IFN-γ responses are
shown. Strong recognition of Ag85B (Rv1886c), PGL/p-HBAD biosynthesis glycosyltransferase (Rv2958c), PGL/p-HBAD biosynthesis rhamnosyl-
transferase (Rv2962c) and PPE55 (Rv3347c). Recombinant proteins Ag85A (Rv3804) and Ag85B (Rv1886c) were differentially recognized among
TB + and TB- groups defined by IFN-γ release. The thick lines (inside the boxplots) represent median values.
Table 2 Statistically different cytokine production in
groups 1(TB patients), 2 (patients with other pulmonary
diseases) and 3 (negative TB cases but highly exposed)
Antigen Groups P-value
SEA/B Group1 vs Group2 0.001
SEA/B Group1 vs Group3 < 0.001
Rv1886c Group1 vs Group3 0.015
Rv2958c Group1 vs Group3 0.020
Rv2958c Group2 vs Group3 0.020
Rv2962c Group1 vs Group3 0.021
Rv2962c Group2 vs Group3 0.021
Rv3347c Group1 vs Group3 0.034
Rv3804c Group1 vs Group3 0.031
Rv1886c Group1 vs Group2 0.016
Rv1886c Group1 vs Group3 0.002
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A different M.tb target recognition pattern defined by IL-
17 production
A more recent study revealed differences between IFN-γ
and IL-17 production in response to M.tb antigens [67].
We selected therefore 14M.tb antigens for further
analysis and tested IL-17 production in response to the
antigens Rv0447, Rv1886c, Rv3019c, Rv2957, Rv2958c,
Rv2962c (peptides) and the recombinant proteins Rv3804c,
Rv1886c, Rv3874, Rv3875, Rv0288, Rv0754, Rv0978a
and Rv1917 (see Figure 2, Table 3, Additional file 1:
Table S1a-c). We were able to demonstrate significantly
different IL-17 production in response to Rv1886c
(Ag85B) in individuals from group 2 (non TB, other re-
spiratory disease) and 3 (health care workers, exposed to
TB) as compared to individuals in group 1 (pulmonary
TB). Immune cells from individuals in group 2 and group
3 produced more IL-17 in response to Rv0978c (PPE family
member), Rv0288 (TB10.4) and Rv1917c (PPE family
member) as compared to blood from individuals with
TB (group 1, patients with pulmonary TB). The highest
IL-17 production was identified in blood from exposed
individuals directed against the antigens listed above.
Analysis between QFT-GIT and bacteriology
We analyzed the cytokine responses in blood from indi-
viduals stratified by the QFT-GIT (see online Additional
file 1: Table S2-4 and Figures S1 and S2) based on the
acid fast stain result, culture positivity and previous history
of TB). Immune cells from individuals with AFS +M.tb +
culture showed decreased IFN-γ responses to the posi-
tive (SEA/SEB) controls. ESAT-6 and CFP-10 immune
reactivity was significantly higher in blood from individ-
uals with AFS- and negative culture results– yet with a
positive QFT-GIT for IFN-γ production (and for IL-17
production in response to Rv3874, CFP10). Significant
differences concerning cytokine response patterns could
Rv1886c Rv0288
Rv0978c Rv1917c
1                    2                   3 1                  2                   3
1                    2                  3 1                  2                   3
IL
-1
7 
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P=0.030
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P=0.002
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P=0.008
Figure 2 IL-17 production shows a different pattern of cellular immune recognition as compared to IFN-γ. IL-17 production in blood
was statistically different in response to the antigens Ag85B (Rv1886c), TB10.4 (Rv0288), PPE - PGR11 (Rv0978c) and PPE34 (Rv1917c).
The thick lines (inside the boxplots) represent median values. Identical patient cohorts as in Figure 1.
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be identified in blood from patients with TB (AFS+, QFT-
GIT + and culture+) versus blood from health care
workers in response to Rv3804c (Ag85A, IFN-γ p = 0.009
as well as for IL-17, p = 0.019) and Rv2962 (pHBAD,
rhamnosyl-transferase, p = 0.042 for IL-17 production)
(Additional file 1: Tables S2-4, Additional file 1: Figures S1
and S2).
Discussion
Tuberculosis is the result of a dynamic host-pathogen
relationship. Anti-M.tb directed immune responses may
be associated with immune-protection, yet also with
immune-pathology, as shown for IL-17-driven cellular
immune responses. IL-17 – associated immune responses
can be protective or harmful in TB and may lead to lung
tissue damage along with massive inflammation and influx
of neutrophils [68]. Most immune assays aim to gauge
M.tb responses measure IFN-γ, which is indispensable
to contain M.tb, yet other immune effector cytokines,
e.g. IL-17, may also be instrumental in immune protec-
tion. Further evidence for the beneficial role of IL-17 is
provided from a pre-clinical model: a recombinant BCG
vaccine expressing listeriolysin, leads to a statistically
significant different IL-17 (yet not IFN-γ) production
[69] in a murine M.tb challenge model.
We were able to show that IFN-γ mediated responses
showed strong cellular recognition of Rv1886c (Ag85B),
Rv3804c (Ag85A), Rv2958c, Rv2962c (enzymes associated
with lipid-alteration) and Rv3347 (PPE family member) in
blood from individuals who have been exposed to M.tb,
yet are clinically healthy. The data are compiled for review
in Table 4 concerning the detailed clinical diagnoses of
individuals enrolled in the study; Table 5 summarizes the
molecularly defined test antigens leading to IFN-γ and
IL-17 production. Decreased IFN-γ production in blood
from individuals with TB (AFS and culture positive) may
in part be related to ‘anergy’, which is reflected in signifi-
cantly lower IFN-γ responses to the positive control
stimulus (SEA/SEB, Figure 1). This notion is further
supported by a more detailed examination of patient
subpopulations (see online Additional file 1: Figure S1
and Table S2). Only blood from individuals with a AFS+,
culture+, QFT-GIT + profile showed decreased IFN-γ
production, this was not found to be true for individuals
with presumably latent TB (based on exposure history,
QFT-GIT+, yet culture - AFS-).
Of interest is the quite different cellular reactivity
concerning M.tb target pattern recognitions if IFN-γ
and IL-17 are analyzed. Ag85B (Rv1886c) showed a
similar trend concerning T-cell recognition, both for
IFN-γ and IL-17 production (see Figures 1 and 2). Yet
the antigen Rv0288 (TB10.4) and two PPE family members
(Rv0978c, Rv1917c) exhibited only statistical differences in
IL-17 responses, yet not concerning the capacity to induce
IFN-γ production. Vice versa, the PPE family member
Rv3347c, the enzymes Rv2958c (glycosyl-transferrase) and
Rv2962 (rhamosyl-transferase) showed only differences
in IFN-γ production between the populations (groups 1,
TB + and 3, health care workers). The data consolidate
our previous observations in a population from Belarus,
where cellular immune responses, defined by IFN-γ
production, were more frequently directed against the
antigen glycsoltransferase (Rv2958c) in healthy individ-
uals frequently exposed to M.tb [70]. The gene product
Rv2958c adds a second rhamnosyl unit and a fucosyl
residue to form the species-specific triglycosyl append-
age of PGL-tb and p-HBAD. A differential expression of
Rv2958c in BCG vaccine strains has been speculated to
be associated with different levels of protection from
TB [71]. The data reported in the current study consoli-
dates also the strong immune recognition of Ag85A in
blood from individuals after BCG vaccination or M.tb
exposure [72].
Several explanations may apply for the differential rec-
ognition patterns defined by IFN-γ and IL-17 production:
Rv2958c and Rv2962 were tested as overlapping peptides;
some peptides may be degraded and therefore not effi-
ciently processed and presented to T-cells; the antigen
processing and presentation of peptides may be different
as compared to recombinant proteins. We produced in
the meantime an (LPS-free) Rv2958c protein which leads
as well as to IL-17 production in blood from TB + individ-
uals (our unpublished data), suggesting that IL-17 produc-
tion may require the intact protein structure and
subsequent cellular processing and presentation.
Other cellular mechanism may be important to initiate
IL-17 production, i.e. the priming and activation of anti-
gen presenting cells which will subsequently present the
recombinant target protein to antigen-specific T-cells. For
instance, the PPE family members (tested in the current
Table 3 Distribution of IFN-γ levels for the antigens
associated with statistically different cytokine production
between groups at 5% level
Antigen Groups P-value
Rv1886c Group1 vs Group2 0.050
Rv1886c Group1 vs Group3 0.029
Rv0288 Group1 vs Group3 0.030
Rv0288 Group2 vs Group3 0.027
Rv0978c Group1 vs Group3 0.003
Rv0978c Group2 vs Group3 0.002
Rv1917c Group1 vs Group3 0.005
Rv1917c Group2 vs Group3 0.008
Differences in IFN-γ between groups were examined using a t-test; adjustment
for multiplicity was applied on the resulting p-values from the tests. (group 1:
TB+, AFS and culture positive, 2: other pulmonary diseases, no exposure
records to TB, 3: health care workers, frequently exposed to M.tb, yet clinically
healthy). Only statistically relevant differences are listed.
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panel) have been shown to mature dendritic cells via
TLR-2 stimulation (in a murine system) leading to a
different quality of antigen-presentation and expansion
of antigen-specific immune cells [62]. A similar obser-
vation has been reported for differences in BCG and
rBCG, expressing listeriolysin; ‘components’ released
from rBCG in the cytosol of macrophages, may lead to a
different array of pathogen-associated signaling patterns
leading to stimulation of antigen-presenting cells and
subsequent expansion of Th17+ immune cells [69]. It
could very well be that the PPE family members described
in the current report lead to different IFN-γ/IL-17
Table 4 Description of the general population, clinical characteristics, microbiology and immunological test results
Group QTF-GIT AF-S Culture X-ray Gender Comments
TB + HIV- n = 38 Pos: 23 Pos: 26 MTB: 23 altered: 23 Female: 17 Pulmonary TB (26), Pleural TB (3) extra-
pulmonary
TB (9)Neg: 10 Neg:12 Neg: 11 non altered: 5 Male: 21
Ind: 5 No data: 0 Cont: 1 No data: 3 no data: 10
TB-HIV- n = 81 Pos: 24 Pos: 0 Neg: 79 altered: 33 Female: 56 Allergy (1) asthma (17), EPOC (20), (non-
TB) pneumonia (8), lung cancer (4), (non-
TB) pleural effusion (1), bronchitis (5),
other (25) otitis, rhinitis, influenza,
diabetes, heart disease.
Neg: 54 Neg: 81 Cont: 1 non altered: 7 Male: 25
Ind: 3 No data: 0 No data: 1 no data: 41
TB-HIV- n = 29 Pos: 11 Pos: 0 Neg: 19 altered: 10 Female: 19 Nurses and TB/HIV health care workers
(19), previous TB with successful
treatment regimen in the past (at least
2 years) but no current TB (10)
Neg: 17 Neg: 19 No data: 10 non altered: 2 Male: 10
Ind: 1 No data:
10
no data: 17
Ind: indeterminate; Neg: negative, Pos: positive.
Table 5 Compilation of the antigen-specific response analysis
Antigen Group 1 Group 2 Group 3
IFN-γ (%) IL-17 (%) IFN-γ (%) IL-17 (%) IFN-γ (%) IL-17 (%)
Rv0447c 10/38 (26) 10/38 (26) 24/81 (30) 17/81 (21) 12/29 (41) 11/29 (38)
Rv2940c 3/38 (8) 8/81 (10) 3/29 (10)
Rv3347c 5/38 (13) 12/81 (15) 12/29 (41)
Rv2453c 4/38 (11) 11/81 (14) 9/29 (31)
Rv1886c 14/38 (37) 10/38 (26) 37/81 (46) 27/81 (33) 15/29 (52) 14/29 (48)
Rv1690 6/38 (16) 18/81 (22) 8/29 (28)
Rv3019c 8/38 (21) 10/38 (26) 29/81 (36) 37/81 (46) 9/29 (31) 16/29 (55)
Rv2957 7/38 (18) 11/38 (29) 30/81 (37) 33/81 (41) 11/29 (38) 12/29 (41)
Rv1085c 6/38 (16) 11/81 (14) 4/29 (14)
Rv0066c 3/38 (8) 14/81 (17) 4/29 (14)
Rv2958c 4/38 (11) 14/38 (37) 10/81 (12) 31/81 (38) 7/29 (24) 13/29 (45)
Rv2962c 3/38 (8) 10/38 (26) 10/81 (12) 32/81 (40) 8/29 (28) 15/29 (28)
Rv1886c 12/25(48) 12/25 (48) 40/65 (62) 47/65 (72) 11/17 (65) 15/17 (88)
Rv3804c 15/25 (60) 15/25 (60) 40/65 (62) 44/65 (68) 12/17 (71) 12/17 (71)
Rv3874 13/20 (65) 8/20 (40) 32/48 (67) 25/48 (52) 13/14 (93) 7/14 (50)
Rv3875 9/20 (45) 8/20 (40) 24/48 (50) 11/48 (23) 6/14 (43) 5/14 (36)
Rv0288 pep 3/11 (27) 3/21 (14) 0/3 (0)
Rv3804c/Rv1886c 3/11 (27) 3/21 (14) 0/3 (0)
Rv3875/3874 7/9 (78) 6/21 (29) 0/5 (0)
Rv0754 3/5 (60) 1/5 (20) 1/17 (6) 5/17 (29) 1/3 (33) 3/3 (100)
Rv0978 2/5 (40) 0/5 (0) 4/17 (24) 5/17 (29) 0/3 (0) 2/3 (66)
Rv1917 2/5 (40) 1/5 (20) 2/17 (12) 7/17 (41) 0/3 (0) 3/3 (100)
Rv0288 1/5 (20) 1/5 (20) 1/17 (6) 6/17 (35) 0/3 (0) 2/3 (66)
Group 1, TB + patients, group 2, TB- other pulmonary diseases, group 3, frequent M.tb exposure, yet clinically healthy.
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production via activation of antigen-presenting cells
(see Figure 2).
Of interest is the strong recognition, defined by IL-17
production, of TB10.4 (Rv0288c) and Ag85B (Rv1886c),
two components of several TB vaccine candidates, in
blood from healthy TB- exposed individuals. A similar,
statistically significant trend, was found to be true for
IL-17 production in response to the PPE family members
Rv0978c (p = 0.003, difference between groups 1 and 3)
and Rv1917c (p = 0.008, difference between groups 1
and 3). Both proteins signal via TLR2 and are able to
mature dendritic cells [62]. Future studies will show
whether recombinant target proteins, used in the
current study, are able to induce critical feedback regula-
tors that would preferentially expand IL-17 –producing
immune cells [12]. The strong TB10.4 recognition in
blood from healthy individuals appears to be in contrast
to the study of Sutherland and coworkers who reported a
significant difference in IFN-γ production, yet not IL-17
production, by comparing cytokine responses in blood
from TB + cases (West Africa) and a TST- control cohort
[67]. Several reasons may account for these differences,
i.e. a different exposure history of the test population to
M.tb and/or environmental mycobacteria and subsequent
expansion of IL-17+ producing immune cells. Not only
exposures to mycobacterial species, yet other (environ-
mental pathogens) may contribute of shaping the immune
response leading to preferential IL-17 production, i.e. nat-
ural killer, natural killer T-cells, lymphoid tissue inducer
and TCRγδ +T-cells are contributing to IL-17 production
(for review see [73]). Future studies may therefore need to
dissect the role of the cell source of IL-17 production in
response to M.tb targets and require the stratification of
immune response analysis based on the distribution of
immune cells subsets (T-cells, NK, NKT, TCRγδ + T-cells)
in the test samples.
Conclusions
In summary, we report for the first time the cellular
immune recognition pattern against M.tb in a clinically
defined Honduran population characterized by differential
immune recognition patterns in regard to IFN-γ and
IL-17 production. The limitations of the current study
are the number of study participants, the difficulty to
obtain age and sex-matched control individuals, to
challenge to gauge and control for multiple M.tb expo-
sures and MOTT, as well as the challenge of defining
latent TB infection in general, particularly in a resource-
restrained country. Of particular interest is the antigen
Rv2958, which is currently being evaluated as part of a
new TB vaccine from our group in pre-clinical models.
Screening of M.tb exposed, yet clinically healthy, individ-
uals (as compared to TB + patients and non-Mtb exposed
control cohorts, such as those described in the current
study) may help to better identify immunological
markers which help to define M.tb exposure and
immune protection.
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